Sensitivity analyses were made with regard to the discount rate, the purchase price of both drugs, the treatment duration with Nivolumab and total QALYs gained over three years.
Næmisgreining var gerð á meðferðarlengd Nivolumab, afvöxtunarprósentu, uppsöfnuðum gæðaárum og innkaupaverði beggja lyfja.